12/1
07:20 am
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/29
01:34 am
ganx
Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]
Medium
Report
Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]
11/20
07:00 am
ganx
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
Medium
Report
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
11/12
08:19 am
ganx
Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 [Seeking Alpha]
Medium
Report
Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 [Seeking Alpha]
11/12
07:00 am
ganx
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Medium
Report
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
11/7
04:17 am
ganx
Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients [Seeking Alpha]
Medium
Report
Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients [Seeking Alpha]
10/30
07:00 am
ganx
Gain Therapeutics to Present at Neuroscience 2025
Medium
Report
Gain Therapeutics to Present at Neuroscience 2025
10/16
07:00 am
ganx
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
Medium
Report
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
10/15
08:12 am
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Medium
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
10/13
08:07 am
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
10/9
08:01 am
ganx
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease [Yahoo! Finance]
Low
Report
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease [Yahoo! Finance]
10/9
07:00 am
ganx
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Low
Report
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
10/7
12:32 pm
ganx
Gain Therapeutics (NASDAQ:GANX) had its price target raised by analysts at Maxim Group from $5.00 to $7.00. They now have a "buy" rating on the stock.
Low
Report
Gain Therapeutics (NASDAQ:GANX) had its price target raised by analysts at Maxim Group from $5.00 to $7.00. They now have a "buy" rating on the stock.
10/6
08:27 am
ganx
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders® [Yahoo! Finance]
High
Report
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders® [Yahoo! Finance]
10/6
08:15 am
ganx
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
High
Report
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
9/23
07:40 am
ganx
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
Low
Report
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
9/18
07:41 am
ganx
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
Medium
Report
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
9/8
08:05 am
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Low
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.